On May 19, on the occasion of the 30th anniversary of AstraZeneca's entry into China, Ali Health and AstraZeneca upgraded their strategic cooperation. The two parties announced that they will further deepen their cooperation on the basis of previous cooperation, build a cardiovascular disease education and rehabilitation platform, and provide customized and innovative digital health management services for patients with chronic diseases.
Cardiovascular disease was one of the first therapeutic areas that AstraZeneca launched when it entered the Chinese market in 1993, and it is also an important part of AstraZeneca's "sugar heart and kidney" joint prevention and control full-course management solution. This time, Ali Health and AstraZeneca have reached a strategic cooperation in the field of cardiovascular diseases. They will take advantage of the business advantages of both parties to jointly explore innovative solutions for the online service ecosystem. With patients as the core and technology as the driving force, we will establish an innovative integrated medical care health service.
As a world-leading well-known pharmaceutical company, AstraZeneca and AliHealth have been working together for five years. Both parties have deep experience in the fields of drug retail, patient education, and Internet diagnosis and treatment. The scope of cooperation covers cardiovascular, metabolism, respiratory, Digestive and Oncology Therapeutic Areas. A number of blockbuster special effects drugs under AstraZeneca have been launched in Ali Health Pharmacy. At the beginning of 2023, Alibaba Health once again joined hands with AstraZeneca and other companies to launch the "buy medicines for chronic diseases without going out" campaign, providing patients with chronic diseases with a special area for direct supply and preparation of medicines from pharmaceutical companies, so as to ensure that patients' medication during special periods will not be affected.
In this strategic cooperation upgrade, AliHealth and AstraZeneca will jointly explore a number of patient services including remote patient education, follow-up services, online consultation, and medication guidance. Each patient is equipped with a "customized" out-of-hospital chronic disease rehabilitation platform, which solves medical and drug purchase needs through digital means, and helps patients manage their own diseases outside the hospital, so that medication compliance and disease control are significantly improved.
In this regard, AstraZeneca's global executive vice president, international business and China president Wang Lei said: "Since AstraZeneca entered China in 1993, it has continued to focus on patients' needs in a wide range of therapeutic areas, accelerating the availability of innovative drugs and serving Chinese patients. In addition, we continue to explore the ecological construction of health innovation, and through cooperation with Internet medical platforms such as Ali Health, we will accelerate the digital layout while helping to create a full-course management solution for the integration of diagnosis and treatment, providing accurate diagnosis and treatment, chronic disease management, and primary care. and multi-scenario medical services bring new ideas and models.”
Zhu Shunyan, chairman and CEO of Ali Health, said at the signing ceremony: "Digitalization is the only effective path for health management. Over the years, the value anchor of Ali Health's digital health management has always been around 'life first', and insisted on doing difficult but correct things. .Based on digital technology and digital operation capabilities, as well as accumulation in the field of health intervention and disease management, we can export full-link digital solutions for important partners like AstraZeneca, and jointly help patients improve their health and quality of life."
According to statistics, AliHealth has cooperated with thousands of pharmaceutical companies around the world, and is the first choice for pharmaceutical companies to explore digital health services. With the upgrade of the strategic cooperation between the two parties, the two parties will jointly explore the long-term value of the digital health field and provide more affordable and accessible medical and health services for patients with chronic diseases.